Get the latest news on Achiko stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on ACHKF performance

Latest Achiko Stock News | OTC:ACHKF | Benzinga

Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Comments

Achiko Stock News

News

Latest Achiko Stock News | OTC:ACHKF | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga